Acute Cardiovascular Effects of (+)-Nantenine, an Alkaloid Isolated from Platycapnos spicata, in Anaesthetised Normotensive Rats

Abstract

This is the first study of the in vivo potential activity of (+)-nantenine (a natural aporphinoid alkaloid) on the rat cardiovascular system. In anaesthetized normotensive rats, acute intravenous (i. v.) administration of (+)-nantenine (3 - 6 mg/kg) produced a dose-dependent fall in mean arterial pressure (MAP), accompanied by a significant decrease in heart rate (HR). In addition, (+)-nantenine (5 mg/kg i. v.) did not modify the cardiovascular effects induced by angiotensin II (0.2 μg/kg i. v.) and the selective α₂-adrenoceptor agonist B-HT 920 (0.2 mg/kg i. v.) [unlike nifedipine (0.8 mg/kg i. v.) and yohimbine (1 mg/kg i. v.), respectively] but markedly attenuated [like prazosin (0.2 mg/kg i. v.)] the hypertension evoked by phenylephrine (PE, 25 μg/kg, i. v.), a selective α₁-adrenergic receptor agonist and, like ketanserin (1 mg/kg i. v.), the second phase (rise in MAP) of the cardiovascular response caused by 5-hydroxytryptamine (5-HT, 0.3 mg/kg i. v.). On the other hand, pre-treatment of anaesthetised rats with N^G -nitro-L-arginine (L-NOARG, 5 mg/kg i. v.) did not significantly affect the cardiovascular effects of (+)-nantenine. These results indicate that the hypotension and bradycardia elicited by this aporphine alkaloid in anaesthetised normotensive rats seem to be due, at least in part, to a combined α₁-adrenergic and 5-HT_2A receptor blockade but not to the release of nitric oxide (NO) from vascular endothelium, to an α₂-adrenoceptor antagonism or to a calcium antagonist activity.

Abbreviations

BP:blood pressure

HR:heart rate

5-HT:5-hydroxytryptamine

i. v.:intravenous

L-NOARG:N^G -nitro-L-arginine

MAP:mean arterial pressure

NO:nitric oxide

PE:phenylephrine

Anaesthetised normotensive rats - bradycardia - hypotension - α-adrenoceptor antagonism - 5-HT_2A receptor blocking properties - (+)-nantenine - aporphine alkaloid

References

• 1 Ríos J L, Simeón S, Villar A. Pharmacological activity of aporphinoid alkaloids. A review.  Fitoterapia. 1989;  5 386-412
• 2 Takase T, Ohashi H. Action of domesticine methyl ether upon peripheral nerves.  J Pharm Soc Japan. 1927;  541 210-4
• 3 Nakai N, Fujii Y, Kobashi K, Nomura K. Aldose reductase inhibitors: flavonoids, alkaloids, acetophenones, benzophenones and spirohydantoins of chroman.  Arch Biochem Biophys. 1985;  239 491-6
• 4 Guinaudeau H, Leboeuf M, Cave A. Aporphinoid alkaloids, IV.  J Nat Prod. 1988;  51 389-474
• 5 Blanco O, Castedo L, Villaverde M C. Alkaloids from Platycapnos spicata .  Phytochemistry. 1993;  32 1055-7
• 6 Orallo F, Fdez-Alzueta A. A. Preliminary study of the vasorelaxant effects of (+)-nantenine, an alkaloid isolated from Platycapnos spicata, in rat aorta.  Planta Med. 2001;  67 800-6
• 7 Orallo F. Pharmacological effects of (+)-nantenine, an alkaloid isolated from Platycapnos spicata, in several rat isolated tissues.  Planta Med. 2003;  69 135-42
• 8 Indra B, Matsunaga K, Hoshino O, Suzuki M, Ogasawara H, Ishiguro M, Ohizumi Y. Structure-activity relationship on (±)-nantenine derivatives in antiserotonergic activities in rat aorta.  Can J Physiol Pharmacol. 2002;  80 198-204
• 9 Ribeiro R, Garcez do Carmo L, Vladimirova I, Jurkiewicz N H, Jurkiewicz A. Nantenine blocks muscle contraction and Ca²⁺ transient induced by noradrenaline and K⁺ in rat vas deferens.  Eur J Pharmacol. 2003;  470 37-43
• 10 Orallo F, Fdez-Alzueta A, Campos-Toimil M, Calleja J M. Study of the in vivo and in vitro cardiovascular effects of (+)-glaucine and N-carbethoxysecoglaucine in rats.  Br J Pharmacol. 1995;  114 1419-27
• 11 Orallo F. Study of the in vivo and in vitro cardiovascular effects of a hydralazine-like vasodilator agent (HPS-10) in normotensive rats.  Br J Pharmacol. 1997;  121 1627-36
• 12 Timmermans P B, Van Zwieten P A. Effects of PN 200 - 110, a new calcium antagonist, on postsynaptic alpha 1- and alpha 2-adrenoceptor in the circulatory system of the pithed rat: selective stimulation of the alpha 2-type by B-HT 933.  Eur J Pharmacol. 1980;  63 199-202
• 13 Aleixandre M A, Puerro M, Pintado A. A comparison of the effects of TMB-8 and nifedipine on pressor responses to alpha 1- and alpha 2-adrenoceptor agonists in pithed rats.  Naunyn Schmiedeberg’s Arch Pharmacol. 1995;  351 500-6
• 14 Saxena P R, Lawang A. A comparison of cardiovascular and smooth muscle effects of 5-hydroxytryptamine and 5-carboxamidotryptamine, a selective agonist of 5-HT₁ receptors.  Arch Int Pharmacodyn Ther. 1985;  277 235-52
• 15 Martin G R. Vascular receptors for 5-hydroxytryptamine: distribution, function and classification.  Pharmacol Ther. 1994;  62 283-324
• 16 Terrón J A. Role of 5-HT₇ receptors in the long-lasting hypotensive response induced by 5-hydroxytryptamine in the rat.  Br J Pharmacol. 1997;  121 563-71
• 17 Villalón C M, De Vries P, Saxena P R. Serotonin receptors as cardiovascular targets.  Drugs Discov Today. 1997;  2 294-300
• 18 Gil-Longo J, Fdez-Grandal D, Álvarez M, Sieira M, Orallo F. Study of in vivo and in vitro resting vasodilator nitric oxide tone in normotensive and genetically hypertensive rats.  Eur J Pharmacol. 1996;  310 175-83
• 19 Orallo F, Rosa E, García-Ferreiro T, Campos-Toimil M, Loza M I, Cadavid I. Comparative study of the in vivo and in vitro cardiovascular effects of ketanserin in rats.  Gen Pharmacol. 2001;  35 95-105
• 20 Pierce V, Shepperson N B, Todd M H, Waterfall J F. Investigation into the cardioregulatory properties of the alpha₁-adrenoceptor blocker indoramin.  Br J Pharmacol. 1986;  87 433-41
• 21 Docherty J R. An investigation of the effects of intravenous injection of the 5-hydroxytryptamine₂ receptor antagonists ketanserin and LY 53 857 on blood pressure in anaesthetized spontaneously hypertensive rats.  J Pharmacol Exp Ther. 1989;  248 736-40
• 22 Champion H C, Czapla M A, Kadowitz P J. Responses to angiotensin peptides are mediated by AT₁ receptors in the rat.  Am J Physiol. 1998;  274 E115-23
• 23 Spedding M. Differences between the effects of calcium antagonists in the pithed rat preparation.  J Cardiovasc Pharmacol. 1982;  4 973-9